Exploring the value of apoB48 as a marker for atherosclerosis in clinical practice

European Journal of Clinical Investigation

Volumn 42, Issue 7, 2012, Pages 702-708

  Alipour, Arash ^a   Valdivielso, Pedro ^b   Elte, Jan Willem F ^a   Janssen, Hans W ^a   Rioja, Jose ^c   van der Meulen, Noëlle ^a   van Mechelen, Rob ^a   Njo, Tjin L ^a   González Santos, Pedro ^b   Rietveld, Arie P ^a   Cabezas, Manuel Castro ^a  

^a SINT FRANCISCUS GASTHUIS   (Netherlands)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^c UNIVERSITY OF MÁLAGA   (Spain)

Author keywords

Apolipoprotein B48; Coronary artery disease; Familial lipid disorders; Intima media thickness; Type 2 diabetes mellitus

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN B48; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; CLINICAL PRACTICE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE MARKER; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

AGED; ANALYSIS OF VARIANCE; APOLIPOPROTEIN B-48; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CAROTID INTIMA-MEDIA THICKNESS; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; HUMANS; HYPERLIPIDEMIA, FAMILIAL COMBINED; MALE; MIDDLE AGED;

EID: 84862591461     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2011.02635.x     Document Type: Article

References (44)

1. Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation 1979;60:473-85.
2. Gianturco SH, Bradley WA. Lipoprotein-mediated cellular mechanisms for atherogenesis in hypertriglyceridemia. Semin Thromb Hemost 1988;14:165-9.
3. Patsch JR, Miesenböck G, Hopferwieser T, Mühlberger V, Knapp E, Dunn JK et al. Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. Arterioscler Thromb 1992;12:133613-45.
4. Karpe F, Steiner G, Uffelman K, Olivecrona T, Hamsten A. Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis 1994;106:83-97.
5. van Wijk JP, Halkes CJ, Erkelens DW, Castro Cabezas M. Fasting and daylong triglycerides in obesity with and without type 2 diabetes. Metabolism 2003;52:1043-9.
6. Howard BV. Lipoprotein metabolism in diabetes mellitus. J Lipid Res 1987;28:613-28.
7. Castro Cabezas M, de Bruin TW, Jansen H, Kock LA, Kortlandt W, Erkelens DW. Impaired chylomicron remnant clearance in familial combined hyperlipidemia. Arterioscler Thromb 1993;13:804-14.
8. Simons LA, Dwyer T, Simons J, Bernstein L, Mock P, Poonia NS et al. Chylomicrons and chylomicron remnants in coronary artery disease: a case-control study. Atherosclerosis 1987;65:181-9.
9. Meyer E, Westerveld HT, de Ruyter-Meijstek FC, van Greevenbroek MM, Rienks R, van Rijn HJ et al. Abnormal postprandial apolipoprotein B-48 and triglyceride responses in normolipidemic women with greater than 70% stenotic coronary artery disease: a case-control study. Atherosclerosis 1996;124:221-35.
10. Weintraub MS, Eisenberg S, Breslow JL. Different patterns of postprandial lipoprotein metabolism in normal, type IIa, type III, and type IV hyperlipoproteinemic individuals. Effects of treatment with cholestyramine and gemfibrozil. J Clin Invest 1987;79:1110-9.
11. Rubinsztein DC, Cohen JC, Berger GM, van der Westhuyzen DR, Coetzee GA, Gevers W. Chylomicron remnant clearance from the plasma is normal in familial hypercholesterolemic homozygotes with defined receptor defects. J Clin Invest 1990;86:1306-12.
12. Eriksson M, Angelin B, Henriksson P, Ericsson S, Vitols S, Berglund L. Metabolism of lipoprotein remnants in humans. Studies during intestinal infusion of fat and cholesterol in subjects with varying expression of the low density lipoprotein receptor. Arterioscler Thromb 1991;11:827-37.
13. Castro Cabezas M, de Bruin TW, Westerveld HE, Meijer E, Erkelens DW. Delayed chylomicron remnant clearance in subjects with heterozygous familial hypercholesterolaemia. J Intern Med 1998;244:299-307.
14. Verseyden C, Meijssen S, Castro Cabezas M. Effects of atorvastatin on fasting plasma and marginated apolipoproteins B48 and B100 in large, triglyceride-rich lipoproteins in familial combined hyperlipidemia. J Clin Endocrinol Metab 2004;89:5021-9.
15. Alipour A, van Oostrom AJ, Izraeljan A, Verseyden C, Collins JM, Frayn KN et al. Leukocyte activation by triglyceride-rich lipoproteins. Arterioscler Thromb Vasc Biol 2008;28:792-7.
16. Gower RM, Wu H, Foster GA, Devaraj S, Jialal I, Ballantyne CM et al. CD11c/CD18 expression is upregulated on blood monocytes during hypertriglyceridemia and enhances adhesion to vascular cell adhesion molecule-1. Arterioscler Thromb Vasc Biol 2011;31:160-6.
17. Smith D, Watts GF, Dane-Stewart C, Mamo JC. Post-prandial chylomicron response may be predicted by a single measurement of plasma apolipoprotein B48 in the fasting state. Eur J Clin Invest 1999;29:204-9.
18. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997;96:1432-7.
19. World Health Organization. Familial Hypercholesterolaemia (FH): Report of a WHO Consultation. Geneva: World Health Organization; 1998.
20. [No author listed] Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997;20:1183-97.
21. Valdivielso P, Puerta S, Rioja J, Alonso I, Ariza MJ, Sánchez-Chaparro MA et al. Postprandial apolipoprotein B48 is associated with asymptomatic peripheral arterial disease: a study in patients with type 2 diabetes and controls. Clin Chim Acta 2010;411:433-7.
22. Kinoshita M, Kojima M, Matsushima T, Teramoto T. Determination of apolipoprotein B-48 in serum by a sandwich ELISA. Clin Chim Acta 2005;351:115-20.
23. Stein JH, Korcarz CE, Hurst RT, Lonn E, Kendall CB, Mohler ER et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. J Am Soc Echocardiogr 2008;21:93-111.
24. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001;358:2026-33.
25. Talmud PJ, Hawe E, Miller GJ, Humphries SE. Nonfasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men. Arterioscler Thromb Vasc Biol 2002;22:1918-23.
26. Sharrett AR, Patsch W, Sorlie PD, Heiss G, Bond MG, Davis CE. Associations of lipoprotein cholesterols, apolipoproteins A-I and B, and triglycerides with carotid atherosclerosis and coronary heart disease. The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb 1994;14:1098-104.
27. Gianturco SH, Bradley WA, Gotto AM Jr, Morrisett JD, Peavy DL. Hypertriglyceridemic very low density lipoproteins induce triglyceride synthesis and accumulation in mouse peritoneal macrophages. J Clin Invest 1982;70:168-78.
28. Proctor SD, Mamo JC. Retention of fluorescent-labelled chylomicron remnants within the intima of the artery wall - evidence that plaque cholesterol may be derived from post-prandial lipoproteins. Eur J Clin Invest 1998;28:497-503.
29. Karpe F, Boquist S, Tang R, Bond GM, de Faire U, Hamsten A. Remnant lipoproteins are related to intima-media thickness of the carotid artery independently of LDL cholesterol and plasma triglycerides. J Lipid Res 2001;42:17-21.
30. Sharrett AR, Chambless LE, Heiss G, Paton CC, Patsch W. Association of postprandial triglyceride and retinyl palmitate responses with asymptomatic carotid artery atherosclerosis in middle-aged men and women. The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol 1995;15:2122-9.
31. Pal S, Semorine K, Watts GF, Mamo J. Identification of lipoproteins of intestinal origin in human atherosclerotic plaque. Clin Chem Lab Med 2003;41:792-5.
32. Nakano T, Nakajima K, Niimi M, Fujita MQ, Nakajima Y, Takeichi S et al. Detection of apolipoproteins B-48 and B-100 carrying particles in lipoprotein fractions extracted from human aortic atherosclerotic plaques in sudden cardiac death cases. Clin Chim Acta 2008;390:38-43.
33. Vazquez Figueroa JG, Rinehart S, McCree A, Teramoto T, Matsushima T, Kinoshita M et al. First quantification of intestinal-apoB48 and hepatic-apoB100 particles in human atherosclerotic plaque by dual immunofluorescence staining. Circulation suppl 2010;16886 Available at:
34. Lamarche B, Moorjani S, Lupien PJ, Cantin B, Bernard PM, Dagenais GR et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular study. Circulation 1996;94:273-8.
35. Shai I, Rimm EB, Hankinson SE, Curhan G, Manson JE, Rifai N et al. Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women: potential implications for clinical guidelines. Circulation 2004;110:2824-30.
36. Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA 2005;294:326-33.
37. Otokozawa S, Ai M, Van Himbergen T, Asztalos BF, Tanaka A, Stein EA et al. Effects of intensive atorvastatin and rosuvastatin treatment on apolipoprotein B-48 and remnant lipoprotein cholesterol levels. Atherosclerosis 2009;205:197-201.
38. Lamon-Fava S, Diffenderfer MR, Barrett PH, Buchsbaum A, Matthan NR, Lichtenstein AH et al. Effects of different doses of atorvastatin on human apolipoprotein B-100, B-48, and A-I metabolism. J Lipid Res 2007;48:1746-53.
39. Tremblay AJ, Lamarche B, Hogue JC, Couture P. Effects of ezetimibe and simvastatin on apolipoprotein B metabolism in males with mixed hyperlipidemia. J Lipid Res 2009;50:1463-71.
40. Parhofer KG, Laubach E, Barrett PH. Effect of atorvastatin on postprandial lipoprotein metabolism in hypertriglyceridemic patients. J Lipid Res 2003;44:1192-8.
41. Ishigami M, Yamashita S, Sakai N, Hirano K, Hiraoka H, Nakamura T et al. Atorvastatin markedly improves type III hyperlipoproteinemia in association with reduction of both exogenous and endogenous apolipoprotein B-containing lipoproteins. Atherosclerosis 2003;168:359-66.
42. Couillard C, Bergeron N, Pascot A, Alméras N, Bergeron J, Tremblay A et al. Evidence for impaired lipolysis in abdominally obese men: postprandial study of apolipoprotein B-48- and B-100-containing lipoproteins. Am J Clin Nutr 2002;76:311-8.
43. Dane-Stewart CA, Watts GF, Mamo JC, Dimmitt SB, Barrett PH, Redgrave TG. Elevated apolipoprotein B-48 and remnant-like particle-cholesterol in heterozygous familial hypercholesterolaemia. Eur J Clin Invest 2001;31:113-7.
44. Tremblay AJ, Lamarche B, Ruel I, Hogue JC, Bergeron J, Gagné C et al. Lack of evidence for reduced plasma apo B48 catabolism in patients with heterozygous familial hypercholesterolemia carrying the same null LDL receptor gene mutation. Atherosclerosis 2004;172:367-73.